Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2024 14:03 ET | Quelle: Research and Markets

Global $111+ Billion Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis 2024-2034 - Rapid Growth in Exon-Skipping Therapies Reflects Precision Medical Interventions Fueled by R&D

Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Duchenne Muscular Dystrophy Drugs Market by Drug Type, by Distribution Channel, and By Region" report has been added to ...
07. Dezember 2022 06:48 ET | Quelle: Research and Markets

Rare Neuromuscular Diseases(NMD) Emerging Pipeline Therapeutics Analysis Report 2022 with Focus on ALS, MG, DMD, SMA, DN & CIDP

Dublin, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The "Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering. Biologics...
28. März 2017 11:41 ET | Quelle: Scott + Scott, Attorneys at Law, LLP

Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta...
27. April 2016 13:38 ET | Quelle: The Race to Yes

Race to Yes Underscores Evidence Presented at FDA Advisory Committee Meeting for Duchenne Muscular Dystrophy Drug Eteplirsen

Organization Urges FDA to Use the Evidence Presented by Dozens of Scientists, Physicians, Patients and Advocates as Required by 2012 FDASIA Act for Conditional Approval Experts Remind Duchenne...